
Sarepta and Roche will share the monitors' findings with EMA to resolve a temporary hold. Elsewhere, Allakos agreed to a buyout and high-dose Ocrevus missed a study goal.

Sarepta and Roche will share the monitors' findings with EMA to resolve a temporary hold. Elsewhere, Allakos agreed to a buyout and high-dose Ocrevus missed a study goal.
Run smarter ELISAs with better data, fewer errors, and faster results. This comprehensive ELISA guide…
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…
News Eli Lilly has entered a collaboration with Seamless Therapeutics worth up to $1.12 billion to co-develop gene editing therapies…
Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling…
Tokyo-based Elix (founded 2016) has launched Elix Discovery, an AI drug discovery platform powered by federated learning models trained on…
The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the…
Sign in to your account